We are rapidly approaching the 18th Congress of IXA in Geneva, September 30 – October 3, 2025! The local organizing committee has done a superb job in attracting dozens of invited speakers and over 180 abstracts submitted to fill our exciting program. Our thanks for their hard work!


REGISTRATION IS NOW OPEN!
Take advantage of the Early-bird discount today!

Program Highlights Include:

  • Advanced technologies in clinical xenotransplantation: Genetics and multi-omics
  • Ethics-economics-regulation – with speakers from regulatory groups
  • Sessions on Coagulation, Complement, and Innate, Adaptive and Humoral immunity
  • Immunosuppression, New Drugs, and Immune Monitoring
  • Microbiology and Safety
  • Physiology and Compatibility
  • Clinical trials design
  • Numerous abstract sessions with expert moderators
  • Late breaking sessions and new achievements

Attention Trainees and Early-Career Professionals

IXA wants you to get the most out of your participation!
The IXA 2025 Congress offers a dynamic program tailored for young investigators, providing numerous opportunities for professional development, networking, and engagement in the field of xenotransplantation.

In addition to these activities, we have fun social events and lovely local hotels within walking distance from the lake! We look forward to seeing you there!!

Meet & Greet Lunch with the Young Investigator Committee

Tuesday, September 30 | 12:30-13:30
The IXA 2025 Congress offers a dynamic program tailored for young investigators, providing numerous opportunities for professional development, networking, and engagement in the field of xenotransplantation.

Mentoring the Future: A Session to Inspire Young Investigators

Thursday, October 2 | 17:05–18:35
A session featuring leading experts discussing cutting-edge topics such as breeding vs. cloning, blastocyst complementation, xenograft pathology, and initial clinical experiences with kidney xenotransplantation. The session includes engaging talks and an interactive panel discussion, offering attendees scientific insights and career reflections from pioneers in the field.

Young Investigator Networking

(proceeding the Congress Networking Event)
Thursday, October 2 | 19:00–20:00 | Bateau Genève (Quai Gustave-Ador 1)
An informal evening aboard the Bateau Genève, featuring ice-breaker games such as a "Young vs. Senior Investigator" trivia or Jeopardy-style quiz. This relaxed setting provides an opportunity to meet new colleagues, share ideas, and initiate collaborations

Fun Run & Walk

Wednesday, October 1 | 7am departure from Bain des Pâquis
Join the Young Investigator Committee for a relaxed 5 km (3 mile) run or walk along scenic Lake Geneva—open to all fitness levels!

Jay A. Fishman, MD

IXA President-Elect
Associate Director, MGH Transplant Center
Massachussetts General Hospital
In other news, IXA has completed a series of “white papers” on topics in xenotransplantation. These have been published simultaneously in the journals of IXA and TTS, Xenotransplantation and Transplantation. These papers have been the subject of a joint TTS and IXA webinar – which was recorded and is available for your review. www.tts.org/ixa-about/ixa-white-papers
In addition, an ISHLT document on heart and lung xenotransplantation is under editorial review. A key function of IXA is to assure that safety of xenotransplantation – sharing best practices and research. We are engaged in updating guidance documents which should be useful both for investigators and regulatory bodies in developing clinical trials and research programs. Among recent papers worth review:

The field is excited by recent innovations in xenotransplantation, including introduction of source pig genetic modifications, novel immunosuppressive strategies, and open discussions of ethical and regulatory frameworks to support translation to the clinic. Porcine renal xenotransplantation for end-stage renal disease (ESRD) relies upon pig kidney xenograft survival beyond 1-year post-transplantation in nonhuman primate (NHP) models and ongoing survival approaching 6 months with a pig-to-human renal graft. These early successes will clarify microbiological risks, if any, posed by porcine xenografts. In the USA, FDA approval of several human clinical trials has spurred excitement at multiple centers. Additional commercial biosecure swine breeding facilities are under development.

We expect new data presented in Geneva to further advance our field!

Don’t forget to renew your membership in IXA!!

Social

Address

International Xenotransplantation Association
C/O The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada